Optimal Duration for the Use of 0.5% LevofloxacinEye Drops Before Vitreoretinal Surgery.
To investigate various regimens of prophylactic antibiotic therapy for vitreoretinal surgery.



This study compared different prophylactic therapies with 0.5% levofloxacin eye drops.



Two hundred nine patients from 7 hospitals scheduled to undergo vitreoretinal surgery were randomized into 3 groups to receive 0.5% levofloxacin eye drops for 1 day (6 times/d), 2 days (3 times/d), or 3 days (3 times/d) before surgery (groups 1D, 2D, and 3D, respectively). all patients received 3 applications of levofloxacin eye drops at 15-minute intervals beginning 1 hour before surgery and conjunctival sac disinfection with 5.0% povidone-iodine 15 minutes before surgery. conjunctival swabs were cultured before levofloxacin therapy (T0), on the morning of surgery (T1), after povidone-iodine disinfection (T2), immediately after surgery (T3), 1 day postoperatively (T4), and 1 week postoperatively (T5).



The positive bacterial culture rates in groups 1D, 2D, and 3D fell, respectively, from 37.33%, 30.77%, and 31.88% at t0 to 10.67%, 12.31%, and 11.59% at t1 and 1.33%, 0%, and 0% at T2. at each time point (T0-T5), there were no significant differences among the groups in positive bacterial culture rate. the bacterial eradication rates in groups 1D, 2D, and 3D were, respectively, 100%, 94.74%, and 90.00% at T1 (after levofloxacin) and 100% in all groups at T2 (after povidone-iodine).



The efficacy of levofloxacin in preventing postoperative infection was similar in the 3 treatment groups. it is recommended that 0.5% levofloxacin be used for only 1 day before vitreoretinal sur-gery (6 times/d) to minimize the use of prophylactic antibiotics.
Peking university People's Hospital, Beijing.
Xiaoxin
X
Li
Yat-sen Ophthalmic Center of Sun Yat-Sen University, Guangzhou.
Xiaoling
X
Liang
Xiangya second Hospital of Central South University, Changsha.
Luosheng
L
Tang
Sichuan University Huaxi Hospital, Chengdu.
Junjun
J
Zhang
Eye Hospital of Wenzhou Medical University, Wenzhou.
Lijun
L
Shen
Second Hospital of Jilin University EyeHospital, Changchun.
Guanfang
G
Su
Eye Center of Tianjin Medical University, Tianjin, China.
Xiaorong
X
Li
D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D019072:Antibiotic Prophylaxis / Q000379:methods*; D001419:Bacteria / Q000302:isolation & purification; D003228:Conjunctiva / Q000382:microbiology; D015818:Eye Infections, Bacterial / Q000517:prevention & control*; D005260:Female; D006801:Humans; D064704:Levofloxacin / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D011183:Postoperative Complications / Q000517:prevention & control*; D013997:Time Factors; D057586:Vitreoretinal Surgery / Q000379:methods*
D000900:Anti-Bacterial Agents; D009883:Ophthalmic Solutions; D064704:Levofloxacin
antibiotic; central retinal artery occlusion; levofloxacin; prophylaxis; vitreoretinal surgery